English | Español

Pharmaceuticals

+ Pharmaceuticals
Patient Daily | Feb 17, 2025

Neuroblastoma patient shows record remission after CAR T cell therapy
+ Regulatory
Patient Daily | Feb 14, 2025

Spokesperson for Patients Come First: 340B program is ‘one of the most blatant abuses of a governmental program’
+ Pharmaceuticals
Patient Daily | Feb 14, 2025

LaTanya Love named interim president of UTHealth Houston
+ Pharmaceuticals
Patient Daily | Feb 14, 2025

UT System appoints interim president for UTHealth Houston
+ Pharmaceuticals
Patient Daily | Feb 14, 2025

UTHealth Houston President Giuseppe N. Colasurdo announces resignation
+ Pharmaceuticals
Patient Daily | Feb 13, 2025

Child diagnosed with rare disorder after genome sequencing reveals chromosomal reshuffling
+ Pharmaceuticals
Patient Daily | Feb 13, 2025

UT System initiates search for new president at UTHealth Houston
+ Pharmaceuticals
Patient Daily | Feb 12, 2025

Research reveals how MAGE-4 aids lung cancer progression

Trending
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
+ Pharmaceuticals
Patient Daily | Aug 7, 2026

Researchers develop computer model linking brain chemistry to neural activity patterns